News

Many HS patients still require more aggressive or advanced treatments due to incomplete response to current options.

Mary W. Chang, MD, discusses the expanded FDA approval of ruxolitinib cream for children with atopic dermatitis and its role in addressing treatment gaps, safety, and real-world use.

Miiskin integrates generative AI into dermatology, enhancing efficiency and patient access while reducing clinician workload and administrative tasks.

Learn more about the in-depth topics covered in the September 2025 print issue of Dermatology Times.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Phase 3 PROTOSTAR data support new indications, expanding treatment options for children impacted by chronic immune-mediated diseases.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about upadacitinib's phase 3 efficacy in alopecia, APG777 as a potential breakthrough in AD, the latest conference insights, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the latest advancements and expert insights from the Maui Derm NP+PA Fall 2025 conference in Nashville, Tennessee.

Rural patients face critical delays in dermatology care, highlighting the urgent need for expanded access and support for NPs and PAs in underserved areas.

Upadacitinib shows promising results in treating severe alopecia areata, achieving significant hair regrowth and setting new efficacy standards in therapy.

Bambusa Therapeutics reveals promising phase I trial results for BBT001, targeting atopic dermatitis with dual-action bispecific antibodies.

Virginia Sybert, MD, emphasizes the importance of judicious genetic testing in pediatric dermatology, advocating for collaboration to enhance patient care.

Derm Dispatch host Renata Block, DMSc, MMS, PA-C, and Buchi Neita, MCMSc, PA-C, discuss how to revolutionize dermatology with lifestyle medicine, enhancing skin health and overall well-being.

TRIV-509 is a dual KLK5/7 inhibitor that aims to address barrier dysfunction, inflammation, and itch in moderate to severe AD.

Explore how dermatology PAs and NPs are transforming patient care through technology, advocacy, and peer education with Andrew Baker, MBA, MPAS, PA-C.

This episode explores the controversy and lack of clear diagnostic criteria for TSW.

As we celebrate National APP Week, Melodie Young, MSN, A/GNP-C, highlights the evolution of dermatology NPs and PAs, emphasizing their vital role in patient care and ongoing professional development.

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, shares how Apex Skin’s multi-site model advances clinical trial access, diversity, and execution.

Bristol Myers Squibb expands direct-to-patient pricing for deucravacitinib and apixaban, enhancing access and affordability for patients in need.

Explore cutting-edge insights from DERM 2025, focusing on innovative treatments and emerging research in dermatology for improved patient care.

Elena Hawryluk, MD, PhD, shares groundbreaking insights on pediatric dermatology and melanoma management at Maui Derm NP+PA, emphasizing innovative treatments.

Jerry Shapiro, MD, shares innovative strategies for diagnosing and managing scarring alopecia at Maui Derm NP+PA Fall 2025, enhancing patient outcomes.

By targeting IL-13, APG777 may allow for less frequent dosing compared to existing biologics.

Todd Schlesinger, MD, FAAD, FASMS, moderated an engaging discussion with colleagues to discuss complex vitiligo cases during a Dermatology Times Case-Based Roundtable event.

Discover educational insights on blistering diseases and innovative treatments like dupilumab at the Maui Derm NP+PA Fall 2025 conference.

Kara Mudd, PA-C, shares vital insights on atopic dermatitis, rosacea, and contact dermatitis from Maui Derm NP+PA Fall 2025, enhancing clinical practice.